Woolworths Group has put forward its own non-binding bid to acquire Priceline owner Australian Pharmaceutical Industries at a cash price of $1.75 per security โ a 20c per share premium on Wesfarmersโ $1.55 per security offer.
According to Woolworths, APIโs board has determined their proposal is likely to be superior to Wesfarmersโ, and it is working to โquicklyโ finalise its due diligence enquiries.
โThere is a compelling strategic rationale to support Woolworths Groupโs acquisition of API,โ said Woolworths Group CEO Brad Banducci.
โHealth and wellbeing is a large, fast-growing category and API would be a fantastic addition to our food and everyday needs ecosystem.
โWe are strongly committed to supporting the community pharmacy model including pharmacy ownership and location rules to ensure pharmacies are well represented in all communities, especially in regional and remote parts of Australia.โ
Woolworthโs play is the latest in a string of acquisition offers for API, from aย proposed merger with Sigma in 2018, to an offer ofย acquisition from Wesfarmers in 2021, which wasย rivalled by Sigma, and now Woolworths.
According to Wesfarmers, its aim for the buy-up is to enable the conglomerate to enter the โgrowing health, wellbeing and beauty sectorโ, according to managing director Rob Scott.
โThe combination of Wesfarmers and API is a compelling opportunity to capitalise on APIโs strengths and positioning in these markets while drawing upon Wesfarmersโ capabilities in retail and distribution, our strong balance sheet and our willingness to invest in our business for growth over the long term,โ said Scott.
This article was first published by Inside Retail.
Comments